Suggestions for secondary innovations and generic development for drugs from the perspective of patent — taking HIV protease inhibitor lopinavir as an example
10.11665/j.issn.1000-5048.20150419
- VernacularTitle:从专利视角谈药物二次创新与仿制药开发——以HIV蛋白酶抑制剂洛匹那韦为例
- Author:
Qian YANG
1
;
Qiujuan MA
;
Xiaojian WANG
Author Information
1. 国家知识产权局专利局专利审查协作北京中心
- Publication Type:Journal Article
- Keywords:
patent;
drug development;
protease inhibitors;
lopinavir;
drug combination
- From:
Journal of China Pharmaceutical University
2015;46(4):499-503
- CountryChina
- Language:Chinese
-
Abstract:
Protease inhibitors(PIs)are a class of antiviral drugs widely used for the treatment of HIV/AIDS. The status of intellectual property of HIV protease inhibitors lopinavir is briefly reviewed in this paper. Based on the indication of Kaletra® , the follow-up studies and generic development of PIs were discussed. It was concluded that the combination of PIs and anti-bacterial/anti-fungal drugs with CYP450 inhibitory effects would be of great use for AIDS and the infectious complications, in the hope of seeking the secondary innovation of other drugs with expired patents in the fields of drug combination and indication expansion.
